GLP-1 maintenance after weight loss: what the data says

What did @therealdrleemd actually say?

The creator claims that after hitting your goal weight on a GLP-1, you can use "maintenance doses" - either taking a standard dose once monthly instead of four times a month, or smaller "micro doses" weekly. They cite that "the vast majority of people regain up to two-thirds of the weight back" after stopping GLP-1 medications, and pitch their practice as an affordable alternative to competitors charging "an arm and a leg."

The core argument is that dose reduction, rather than full cessation, is a smarter exit strategy. That's not an unreasonable clinical premise. But the specific dosing claims - monthly tirzepatide injections, unspecified microdoses - are presented without any supporting evidence, and the framing leans heavily toward a sales pitch wrapped in a science costume.

Does the science back this up?

The weight regain statistic is largely accurate. The maintenance dosing strategy has some theoretical basis, but the evidence for the specific protocols described here is essentially nonexistent.

The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide after 36 weeks regained a substantial portion of lost weight, while those who continued lost more. The STEP 4 trial (Rubino et al., 2021, JAMA) with semaglutide confirmed similar patterns: discontinuation led to regaining roughly two-thirds of lost weight within a year. So the creator's rebound statistic is grounded in real data.

However, no published trial has tested monthly tirzepatide dosing for weight maintenance. Tirzepatide has a half-life of approximately five days. Injecting it once monthly would result in near-complete elimination before the next dose, which is pharmacologically very different from the weekly dosing studied in trials. The "microdosing" claim has even less clinical backing.

What did they get wrong (or right)?

They got the weight regain data right. That's the strongest part of this video, and it's an important thing for patients to know. Credit where it's due.

What they got wrong - or at minimum unsubstantiated - is the specific maintenance dosing protocols. Describing a once-monthly tirzepatide injection as equivalent to standard maintenance is not supported by pharmacokinetic data or clinical trials. Tirzepatide's half-life means that a monthly injection would leave patients with near-zero drug exposure for roughly three weeks of each cycle. The creator presents this as a straightforward dose reduction when it is functionally closer to intermittent therapy, which has not been validated.

The "microdosing" framing is also a red flag. This term has no standardized clinical definition in GLP-1 literature and is often used in direct-to-consumer telehealth marketing to suggest customization and affordability without specifying what doses are actually being prescribed or whether they fall within studied therapeutic ranges.

It is also worth noting: compounded tirzepatide is not the same as FDA-approved Zepbound or Mounjaro. Presenting compounded formulations as interchangeable maintenance options without that distinction is misleading to patients.

What should you actually know?

Weight regain after stopping GLP-1s is a real, well-documented problem - not a scare tactic. The biology makes sense: GLP-1 receptor agonists suppress appetite and alter gut signaling in ways that largely reverse when the drug leaves your system. Obesity is a chronic condition, and many patients may need long-term treatment, much like hypertension or diabetes management.

The question of how to de-escalate GLP-1 therapy responsibly is genuinely unsettled in the literature. Some clinicians do explore dose reduction strategies, and a 2023 review in Obesity Reviews (Garvey et al.) suggested that lower maintenance doses may help some patients sustain weight loss, but the evidence base is preliminary and does not validate the specific protocols described in this video.

If you are considering stopping or reducing your GLP-1, that conversation should happen with a licensed prescriber who has access to your full health history, not via a TikTok comment section. Monthly dosing of tirzepatide and unspecified microdosing protocols are not established standard of care.